Patents Assigned to Alpha Synergy Development, Inc.
-
Publication number: 20120328687Abstract: The invention provides compositions and methods utilizing low concentrations of selective ?-2 adrenergic receptor agonists, preferably, brimonidine. The invention provides contact lens solutions and methods of using these solutions for pre-soaking contact lenses to achieve reduction of redness and/or increase in whitening of eyes. The invention also provides compositions including a selective ?-2 adrenergic receptor agonist in a combination with an ocular medical device, including but not limited to a bandage lens. The invention also provides combination compositions including a selective ?-2 adrenergic receptor agonist and another active agent for the treatment of an ocular condition, including but not limited to glaucoma and/or a condition associated with eye redness.Type: ApplicationFiled: September 7, 2012Publication date: December 27, 2012Applicant: ALPHA SYNERGY DEVELOPMENT, INC.Inventor: Gerald Horn
-
Patent number: 8338421Abstract: The invention generally relates to compositions and methods for inducing vasoconstriction with low incidence of rebound hyperemia. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.Type: GrantFiled: July 27, 2009Date of Patent: December 25, 2012Assignee: Alpha Synergy Development, Inc.Inventor: Gerald Horn
-
Publication number: 20120309720Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Applicant: Alpha Synergy Development Inc.Inventor: Gerald Horn
-
Publication number: 20120309804Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Applicant: Alpha Synergy Development Inc.Inventor: Gerald Horn
-
Publication number: 20120277239Abstract: The invention provides compositions and methods for improving night vision without inducing redness or significant tachyphylaxis. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine.Type: ApplicationFiled: April 27, 2012Publication date: November 1, 2012Applicant: ALPHA SYNERGY DEVELOPMENT INC.Inventors: Gerald Horn, Lee Nordan
-
Patent number: 8293742Abstract: The invention generally relates to compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.Type: GrantFiled: July 27, 2009Date of Patent: October 23, 2012Assignee: Alpha Synergy Development, Inc.Inventor: Gerald Horn
-
Patent number: 8283350Abstract: The invention generally relates to compositions and methods for reducing capillary permeability. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.Type: GrantFiled: July 27, 2009Date of Patent: October 9, 2012Assignee: Alpha Synergy Development, Inc.Inventor: Gerald Horn
-
Publication number: 20120202864Abstract: The invention provides ?-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred ?-2 agonist used in the inventive compositions and methods is dexmedetomidine at acidic pH and extremely low concentrations.Type: ApplicationFiled: February 2, 2012Publication date: August 9, 2012Applicant: ALPHA SYNERGY DEVELOPMENT INC.Inventor: Gerald Horn
-
Publication number: 20120156244Abstract: Pharmaceutical compositions for the treatment of nasal congestion, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective ?-2 adrenergic receptor agonists. Methods of using the compositions for the treatment of nasal congestion, cerebrovascular disease or systemic conditions, and as delivery vehicles to deliver other active agents to treat systemic or cerebrovascular diseases or conditions.Type: ApplicationFiled: February 27, 2012Publication date: June 21, 2012Applicant: ALPHA SYNERGY DEVELOPMENT INC.Inventor: Gerald Horn
-
Patent number: 8080550Abstract: The invention generally relates to anesthetic compositions comprising low doses of a selective a-2 adrenergic receptor agonists in combination with anesthetic agents. The invention also relates to methods of using these compositions; in particular, the use of these compositions in humans to enhance the efficacy of a local peripheral anesthetic injection. The compositions and the methods are particularly useful in regional block anesthetic injections, and more particularly, in dental anesthetic injections.Type: GrantFiled: July 27, 2009Date of Patent: December 20, 2011Assignee: Alpha Synergy Development, Inc.Inventor: Gerald Horn